BRISBANE, Calif., Dec. 12, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing poly (ADP-ribose) polymerase (PARP) inhibitors as novel cancer therapies, today announced positive interim safety data from an ongoing Phase 2 clinical trial of the company's PARP inhibitor, BSI-201, in combination with chemotherapy in patients with triple negative metastatic breast cancer (TNBC). The company also presented gene expression data that confirmed significant upregulation of PARP in the tumors of the first 50 patients enrolled in the Phase 2 trial. Results were presented in a poster at the 2008 annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.
